C.M. Bidwell & Associates’s Ligand Pharmaceuticals LGND Stock Holding History

C.M. Bidwell & Associates’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-52	Closed	-$5.57K	–	493
2024 Q4	$5.57K	Hold	52	–	–	﹤0.01%	318
2024 Q3	$5.21K	Hold	52	–	–	﹤0.01%	323
2024 Q2	$4.38K	Hold	52	–	–	﹤0.01%	333
2024 Q1	$3.8K	Hold	52	–	–	﹤0.01%	353
2023 Q4	$3.71K	Buy	52 +22	+73%	+$1.3K	﹤0.01%	356
2023 Q3	$1.8K	Sell	30 -1,241	-98%	-$81.7K	﹤0.01%	479
2023 Q2	$91.6K	Buy	1,271 +1,256	+8,373%	+$94.2K	0.07%	251
2023 Q1	$1.1K	Buy	+15	New	+$1.07K	﹤0.01%	492
2020 Q4	–	Sell	-1,111	Closed	-$66K	–	512
2020 Q3	$66K	Sell	1,111 -3,169	-74%	-$216K	0.06%	231
2020 Q2	$299K	Buy	+4,280	New	+$271K	0.27%	80
2019 Q2	–	Sell	-1,755	Closed	-$138K	–	428
2019 Q1	$138K	Buy	+1,755	New	+$133K	0.14%	154
2018 Q4	–	Sell	-409	Closed	-$70K	–	431
2018 Q3	$70K	Sell	409 -8	-2%	-$1.21K	0.07%	212
2018 Q2	$54K	Hold	417	–	–	0.05%	240
2018 Q1	$43K	Buy	+417	New	+$41.2K	0.04%	248

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

C.M. Bidwell & Associates's LGND Position: Q1 2025 in Review

C.M. Bidwell & Associates sold out of Ligand Pharmaceuticals (LGND) in Q1 2025, closing a stake of 52 shares — an estimated $5.57K sold.

C.M. Bidwell & Associates first reported a position in LGND in Q1 2018 and held it in 14 quarters. The position peaked at $299K in Q2 2020. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2025.

C.M. Bidwell & Associates reported no remaining Ligand Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
C.M. Bidwell & Associates sold 52 Ligand Pharmaceuticals shares in Q1 2025, an estimated $5.57K.
C.M. Bidwell & Associates first reported a position in Ligand Pharmaceuticals in Q1 2018 and held it in 14 quarters.
C.M. Bidwell & Associates's Ligand Pharmaceuticals position peaked at $299K in Q2 2020.
262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2025, filed 15 May 2025.